Condition: Breast Cancer · Sponsor: Odonate Therapeutics, Inc.
CONTESSA 2 is a multinational, multicenter, Phase 2 study of tesetaxel in patients with HER2 negative, HR positive, locally advanced or metastatic breast cancer (LA/MBC) not previously treated with a taxane. The primary objective of the study is to establish the efficacy of tesetaxel plus a reduced dose of capecitabine based on objective response rate (ORR) as assessed by an Independent Radiologic Review Committee (IRC). 152 patients were enrolled.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Innovative Clinical Research Institute | Whittier, California, United States | — |
| Rocky Mountain Cancer Center | Lakewood, Colorado, United States | — |
| Sarah Cannon Research Institute - Florida Cancer Specialists | Fort Myers, Florida, United States | — |
| Florida Cancer Specialists and Research Institute | St. Petersburg, Florida, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| New York Cancer and Blood Specialists | East Setauket, New York, United States | — |
| West Cancer Center | Germantown, Tennessee, United States | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas, Texas, United States | — |
| Virginia Oncology Associates | Norfolk, Virginia, United States | — |
| Border Medical Oncology | Albury, New South Wales, Australia | — |
| Hopital Maisonneuve-Rosemont | Montreal, Canada | — |
| Center Hospitalier de Montreal CHUM McPeak Sirois | Montreal, Canada | — |
+ 13 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03858972